On May 13, Gelonghui Pharmaceuticals (300630.SZ) announced that the company recently received the drug registration approval for injectable vancomycin hydrochloride issued by the State Drug Administration. Intravenous infusion of this product is suitable for infections caused by methicillin-resistant Staphylococcus aureus and other bacteria: sepsis, infective endocarditis, osteomyelitis, arthritis, burns, surgical trauma and other superficial secondary infections, pneumonia, lung abscesses, empyema, peritonitis, and meningitis. This product can be taken orally for antibiotic related pseudomembranous colitis and staphylococcal enterocolitis caused by Clostridium difficile, and injectable administration has not been shown to be effective for these two indications. Vancomycin oral administration is not effective for other types of infections.
普利制药(300630.SZ)：注射用盐酸万古霉素获得注册批件
Puri Pharmaceuticals (300630.SZ): Vancomycin hydrochloride for injection obtained registration approval
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.